Assessment of healthcare markets, payer systems and policy to provide advice that will give your product the best chance of success.

• Reimbursement strategy
• PBAC submissions
• Prosthesis and MSAC submssions
• PHARMAC submissions
• Hospital formulary submission
• Market access feasibility studies
• Submissions to reimbursement authorities internationally, including Korea, Taiwan, Japan, Mexico, USA, Scotland, England & Wales, Italy, Germany, Sweden and others
• Global pricing studies

Evaluation and critical appraisal of evidence on the safety and efficacy of new and existing treatment options. This includes:

• Health technology assessment
• Critical assessment of clinical trial evidence
• Systematic literature reviews
• Direct and indirect statistical analyses
• Patient preference determined via discrete choice analysis
• Biostatistics input and interpretation
• Utility studies and willingness to pay studies
• Epidemiological research
• Medical writing
• Adapting clinical trials
• Real world evidence studies

Understanding current price trends for long term commercial success for both new and existing products:

• Pricing strategy
• Risk sharing arrangements
• Post-market analyses
• Price and volume impact assessments

Illuminate has extensive experience in building from scratch and also adapting the full range of economic evaluations and budget impact analyses:

• Build decision analytical models including global models
• Budget impact models
• Model adaptations in Australia and Internationally
• Cost utility analysis; Cost effectiveness analysis; Cost Benefit analysis

Development of proprietary data assets to support the long term commercialisation of many pharmaceutical products:

• Illuminate RED: Longitudinal PBS price/utilisation database, and PBAC decisions

A major part of our expertise is on international projects. These have included the following:

• Multi-country model adaptations
• Multi-country budget impact models
• Global pricing analysis
• Building models which have been adapted internationally